Kuwayama H et al. |
Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17439512
|
Wong WM et al. |
Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15644048
|
Hurenkamp GJ et al. |
Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930901
|
Lai KC et al. |
Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930902
|
Pilotto A et al. |
Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930903
|
Kihira K et al. |
Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930904
|
Gisbert JP et al. |
Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12641497
|
Wong WM et al. |
Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12622764
|
Fischbach L and Evans EL |
Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17635369
|
Meier R et al. |
Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11380323
|
Spinzi G et al. |
Randomized study comparing omeprazole plus amoxycillin versus omeprazole plus clarithromycin for eradication of Helicobacter pylori. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9146769
|
Peterson WL |
The role of antisecretory drugs in the treatment of Helicobacter pylori infection. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9146787
|
Kaneko F et al. |
High prevalence rate of Helicobacter pylori resistance to clarithromycin during long-term multiple antibiotic therapy for chronic respiratory disease caused by non-tuberculous mycobacteria. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15298607
|
Sierra F et al. |
Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. |
2013 |
Aliment. Pharmacol. Ther. |
pmid:23656465
|
Masaoka T et al. |
Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15298608
|
Kondo Y et al. |
Helicobacter pylori eradication decreases blood neutrophil and monocyte counts. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15298609
|
Chiba N et al. |
Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:14984382
|
de Francesco V et al. |
Primary clarithromycin resistance in Italy assessed on Helicobacter pylori DNA sequences by TaqMan real-time polymerase chain reaction. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16423002
|
Di Mario F et al. |
Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16611285
|
Madisch A et al. |
Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16441467
|
Borody TJ et al. |
Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16441468
|
Laine L |
Review article: esomeprazole in the treatment of Helicobacter pylori. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12047270
|
Molina-Infante J et al. |
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:25776067
|
Wong BC et al. |
One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11207516
|
Fakheri H et al. |
Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11207517
|
Nagahara A et al. |
Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11207518
|
Bardhan KD et al. |
Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632646
|
Shokri-Shirvani J et al. |
Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:27137738
|
Park HG et al. |
Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. |
2012 |
Aliment. Pharmacol. Ther. |
pmid:22066530
|
Poon SK et al. |
Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11860412
|
Peitz U et al. |
High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11860415
|
Sheu BS et al. |
Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12197847
|
Calvet X et al. |
One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12144575
|
Calvet X et al. |
A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10792124
|
Spinzi GC et al. |
Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9663722
|
O'Connor HJ et al. |
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9570262
|
Goodgame RW et al. |
Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11736715
|
Malfertheiner P et al. |
Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12752349
|
Gené E et al. |
Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12752350
|
Canducci F et al. |
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11121911
|
Toracchio S et al. |
Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11121913
|
Cammarota G et al. |
Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971300
|
Pilotto A et al. |
Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971305
|
Vcev A et al. |
Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632647
|
Gisbert JP et al. |
Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16556172
|
Gomollón F et al. |
Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11012479
|
De Francesco V et al. |
Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:14871280
|
Klok RM et al. |
Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966514
|
Gisbert JP et al. |
Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. |
2012 |
Aliment. Pharmacol. Ther. |
pmid:22372560
|
Graham DY et al. |
Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12755836
|